Symrise: New Biotechnology Partnership in the US

Corporate news announcement processed and transmitted by Hugin ASA.
The issuer is solely responsible for the content of this 
announcement. 
----------------------------------------------------------------------
--------------    




Symrise, one of the world's leading suppliers of fragrances, active
cosmetic ingredients and flavorings, has acquired a 20 percent stake
in the US biotechnology company Therapeutic Peptides Inc. (TPI), thus
securing exclusive distribution rights for highly advanced cosmetic
active ingredients.

In acquiring a stake in TPI, Symrise gains access to the
ultra-innovative group of active ingredients known as peptides, which
the company can immediately offer to its customers in the
international cosmetics industry. Peptides are used as anti-microbial
substances and in anti-aging skin care products, for example, and
stimulate hair growth. "It is only just recently that peptides have
been used in cosmetic products. We are delighted to be able to
integrate these modern and very effective ingredients in our
portfolio. With TPI, we have found a partner who is developing these
ingredients at a scientifically exalted level and can offer ample
expertise in this field," stated Dr. Klaus Stanzl, President Scent &
Care, Life Essentials. In connection with the Symrise shareholding in
TPI, Klaus Stanzl has also been elected to its Supervisory Board.

With the Symrise stake, the Louisiana-based US company Therapeutic
Peptides Inc. will have fresh resources available for maintaining its
intensive research work. "Symrise is for us the ideal partner. It
opens up worldwide distribution opportunities for our substances,"
declared Dr. Donald Owen, founder and managing director of TPI.

Symrise's stake in TPI represents a further, strategically wise
expansion of its portfolio of cosmetic ingredients. Exclusive
distribution of modern and highly efficient peptides, whose
effectiveness is scientifically proven, will enable the company to
react to the growing demand from its customers in this field.


About Symrise

Symrise is a global supplier of fragrances, flavorings and raw
materials and active ingredients for the perfume, cosmetics and food
industry.

Its sales of ¤1.27 billion in 2007 place the company among the top
four in the international flavors and fragrances market.
Headquartered in Holzminden, Germany, Symrise is represented in more
than 30 countries in Europe, Asia, the United States and South
America.

With more than 40 first patent applications per year, Symrise is one
of the most innovative manufacturers on the market. Used by
manufacturers of perfumes, cosmetics and foods, our products are an
inseparable part of daily life. At Symrise we combine an awareness of
consumer trends with cutting-edge technologies, focusing on
innovative fashion and lifestyle products that have additional
practical value for the consumer. Symrise - always inspiring more.

www.symrise.com

Contact: Katja Derow, phone: [phone], e-mail:
[e-mail]


Therapeutic Peptides Inc.

The until now privately held and managed US biotechnology company
Therapeutic Peptides Inc. specializes in the development and
production of bioactive peptides, peptide derivatives and in a
technology for their transdermal delivery.

The founder of TPI - Dr. Donald Owen - has been engaged in academic
and clinical research for over 30 years. He has served as
co-investigator on various research programs, among other places at
the Medical University of South Carolina and the University of
Southern Mississippi.

www.tpipeptides.com


 
--- End of Message ---

Symrise AG
Mühlenfeldstraße 1 Holzminden Germany

WKN: SYM999; ISIN: 
DE000SYM9999; Index: MDAX, TecDAX;
Listed: Amtlicher Markt in Frankfurter Wertpapierbörse, Freiverkehr 
in Bayerische Börse München, 
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg, Freiverkehr 
in Börse Berlin, 
Freiverkehr in Börse Düsseldorf, Freiverkehr in Börse Stuttgart, 
Prime Standard in Frankfurter Wertpapierbörse;